Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
Anoro® Ellipta® (umeclidinium/vilanterol) gains approval in Japan for the treatment of COPD
GSK & THRX announced that JMHLW has approved Anoro® Ellipta® (umeclidinium/vilanterol) for the relief of various symptoms with COPD
-
GSK receives EU marketing authorisation for Mekinist™ (trametinib) for patients with unresectable or metastatic melanoma with a BRAF V600 mutation
GSK announced, the EC has granted marketing authorisation for trametinib as treatment of patients with unresectable/metastatic melanoma
-
GSK and Genmab receive EU authorisation for Arzerra
GSK & GEN announced today that the EC has granted marketing authorisation for a new indication for the use of Arzerra™ (ofatumumab)...
-
GSK statement in response to recent media coverage related to our China business
Following media coverage, GSK has issued the below statement.
-
GSK statement on UK Government-initiated review of antibiotic resistance
We welcome today’s announcement of a review to explore the economic issues surrounding antimicrobial resistance.
-
GSK and Save the Children offer $1 million award for healthcare innovations in developing countries that reduce child deaths
GSK and Save the Children today announced the launch of their second annual $1 million Healthcare Innovation Award.
-
GSK and Theravance announce submission to US regulatory authorities for fluticasone furoate/vilanterol in asthma
GSK and THRX announced the submission of a new drug application for asthma in patients aged 12 years and older, brand name Breo® Ellipta®.
-
GSK statement on recent media coverage related to our China business
Following media coverage this weekend, GSK has issued the following statement.
-
GSK and Genmab announce top-line results from a Phase III study of ofatumumab versus physicians’ choice for bulky fludarabine-refractory CLL
GSK & GEN announced today that the Phase III study of ofatumumab (Arzerra™) did not meet its primary endpoint of PFS.
-
Triumeq® (dolutegravir/abacavir/lamivudine) single-tablet regimen receives positive CHMP opinion in Europe for the treatment of HIV
ViiV Healthcare today announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion.
-
GSK announces the start of a phase III study with eltrombopag in patients with myelodysplastic syndromes
GSK announced the start of a Phase III study to evaluate effects of eltrombopag with azacitidine versus placebo in patients with MDS.
-
GSK presents new data for once-weekly Tanzeum/Eperzan (albiglutide) showing blood glucose lowering up to three years in type 2 diabetes
Data from four randomised phase III studies show that patients on albiglutide, continued to show blood glucose lowering at three years.
-
GSK announces results of Phase III PETIT2 study of eltrombopag (Promacta™/Revolade™) in paediatric patients with chronic immune thrombocytopenia
GSK announced the results from the Phase III PETIT2 study evaluating efficacy of eltrombopag vs. placebo in paediatric patients with cITP
-
ViiV Healthcare announces new collaboration with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1
ViiV announced they have entered into an agreement with Janssen for the development and commercialisation of Tivicay® Edurant®.
-
GSK and Theravance announce positive data from two studies evaluating the efficacy and safety of Incruse™ Ellipta® when added to Relvar®/Breo® Ellipta® in patients with COPD
GSK and THRX today announced positive results from two phase III studies.
-
GSK announces start of phase III cardiovascular outcomes study with losmapimod in patients with acute coronary syndrome
GSK today announced the start of a pivotal phase III study to evaluate the effects of losmapimod in patients presenting with ACS.
-
GSK announces Phase III ALTTO results for anti-HER2 therapy combination in the adjuvant breast cancer treatment setting
GSK today announced that the Phase III study of two anti-HER2 agents, lapatinib (Tykerb™/Tyverb™) and trastuzumab.
-
Serious Fraud Office Investigation
GSK has today been informed by UK's SFO that it has opened a formal criminal investigation into the Group’s commercial practices.
-
GSK and Genmab receive FDA approval for Arzerra® (ofatumumab)
GSK and Genmab announced today that CHMP of the European Medicines Agency (EMA) has issued a positive opinion recommending a variation.
-
GSK announces regulatory submission for umeclidinium monotherapy for COPD in Japan
GSK announced the submission of a regulatory application to the JMHLW for UMEC, a LAMA, administered using the Ellipta™ dry powder inhaler.
